// App-Quantinova.ai

: Efficacy and Safety of Pirfenidone in Idiopathic Pulmonary Fibrosis According to Dose and Disease Severity

Researchers

Presenter

  • J. Park

Principal Investigators

  • J. Lee

  • S. Choi

  • J. Y. Cho

  • Y. Lee

  • Y. Cho

  • J. Yim

  • C. Lee

  • Y. Kim

  • H. Hwang

Medical Centers

  • Surgery, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

  • Seoul Metroplitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Keimyung University Dongsan Hospital, Daegu, Korea, Republic of

  • Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea, Republic Of,

  • Internal Medicine, Seoul Naitonal University Bundang Hospital, Seongnam, Korea

  • Seoul Natl Univ Bundang Hosp, Gyeongggi-do 463-707, Korea, Republic of,

  • Seoul Natl Univ Hosp, Seoul 110-744, Korea, Republic of.

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved